ClinicalTrials.gg
CompletedNCT01443221Updated Sep 29, 2011

Pharmacokinetics of Mitiglinide and Metformin in Free Combination and Fixed-dose Combination in Healthy Male Subjects.

A Phase 1 interventional study of mitiglinide and metformin and mitiglinide and metformin in Healthy, sponsored by JW Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-09-29.

Sponsored by JW Pharmaceutical · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
Male
01

Study summary

To investigate safety and pharmacokinetics of mitiglinide and metformin in a fixed-dose combination of mitiglinide/metformin, compared with free combination of mitiglinide and metformin in healthy male subjects.

Read the detailed description

The Korean clinical practice guidelines on DM recommend that a second oral agent with a different mechanism of action be combined to the regimen when adequate glycemic control is difficult to achieve with an oral hypoglycemic agent accompanied dietary therapy. Therefore, a concurrent administration of metformin, a inhibitor of gluconeogenesis, and mitiglinide, an insulin secretagogue, could be an effective and ideal regimen for management of diabetes.

02

Conditions studied

  • Healthy

Keywords

  • mitiglinide
  • metformin
  • Pharmacokinetics
  • Safety
03

In context

Lead sponsor

JW Pharmaceutical is the lead sponsor of 77 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males
  • Subject with adequate clinical laboratory test results (hematology, blood chemistry, serology, drug abuse, urinalysis etc.)
  • Subject with normal results in blood pressure, pulse, body temperature and test
  • Subject with (BMI) between 18.5 kg/m2 and to 25 kg/m2

Exclusion criteria

Exclusion Criteria:

  • functional disorder or acute disease
  • Chronic disease affecting the absorption, metabolism or excretion of drug
  • Any study drug administration within 90 days before the first drug administration
  • Use of medicine affecting drug metabolism (inhibition, induction) such as barbital, within 30 days before the first drug administration
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Free combination

    Free combination of Mitiglinide 10mg and Metformin 500mg

    Drug: mitiglinide and metformin

  • Experimental
    Fixed-dose combination

    Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg

    Drug: mitiglinide and metformin

Interventions

  • Drugmitiglinide and metformin

    Drug pages: Mitiglinide · Metformin

    Free combination of Mitiglinide 10mg and Metformin 500mg

  • Drugmitiglinide and metformin

    Drug pages: Mitiglinide · Metformin

    Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg

06

What researchers measure

Primary outcomes

  1. Compare the pharmacokinetic profiles(Cmax, AUClast) of fixed-dose combination versus free dose combination in healthy volunteers

    Time frame: Up to 36 hours postdose for each period

Secondary outcomes

  1. Compare the pharmacokinetic profiles(tmax, t1/2, AUC0-∞) of fixed-dose combination versus free dose combination in healthy volunteers

    Time frame: Up to 36hours postdose for each period

07

Study locations

1 site
  • Samsung Medical Center
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2011
First posted
Sep 29, 2011
Start
Dec 2010
Primary completionActual
Jan 2011
CompletionActual
Jan 2011
Last update
Sep 29, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01443221
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Sep 29, 2011
Start date
Dec 2010
Primary completion
Jan 2011
Completion
Jan 2011
Last update
Sep 29, 2011

Study contacts

Wooseong Hur, MD, PhD
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mitiglinide · Metformin

Start the discussion